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REVIEW
Abstract: Anemia is frequent in cancer patients with chemotherapy, and has an important
negative effect on health-related quality of life (QoL). Darbepoetin alfa belongs to a new
class of erythropoietic proteins with a unique molecular structure and interesting properties
compared with classic recombinant human erythropoietin. Darbepoetin alfa is effective for
chemotherapy-induced anemia when administered once weekly at a dose of 2.25 µg/kg, as
shown in two large phase III placebo-controlled trials in patients with solid tumors and
hematological malignancies. Furthermore, it was safe and well tolerated. More recently
attention has been focused on optimizing Darbepoetin alfa therapy. Front-loaded dosing was
explored to accelerate the hemoglobin (Hb) response and effect on QoL, but this idea could
not be confirmed in a large phase III study. Based on the prolonged half-life of Darbepoetin
alfa, administration every 3 weeks was appealing. In a large phase III trial, noninferiority of
administration of 500 µg every 3 weeks compared with the weekly dosing could be confirmed,
both in terms of reduction of red blood cell transfusion, Hb parameters, and QoL. This schedule
is very convenient for patients and caregivers as it allows synchronization of erythropoietic
therapy and common chemotherapy schedules. Questions for future study are the optimal
iron supplementation strategy and the effect of Darbepoetin alfa on outcome. This article
reviews the clinical development of Darbepoetin alfa with emphasis on recent data.
Keywords: Darbepoetin alfa, erythropoietic therapy, anemia, chemotherapy-induced anemia,
pharmacokinetics, clinical trials, quality of life
Introduction
Anemia, a frequent problem in patients with cancer, has multiple possible causes.
Most cancer patients have anemia related to chronic disease. Other causes are bone
marrow invasion, hemolysis, nutritional deficiencies, bleeding caused by the tumor
or due to treatment-induced coagulopathy. The occurrence of anemia will also be
influenced by the cancer treatment: chemotherapy, especially platinum-containing
chemotherapy and radiotherapy; both can induce anemia. Current cancer therapies
often include dose-intense combination chemotherapy or combined
chemoradiotherapy, resulting in an even more pronounced risk of myelosuppression.
Anemia has important implications for cancer patients. The most common
complaint of a patient with anemia is fatigue and this symptom is known to severely
reduce quality of life (QoL) (Curt 2000; Curt et al 2000). The treatment of anemia
can provide real benefit for the patient improving his QoL and ensuring the best
chances for achieving the planned anti-cancer therapy.
For many years transfusion was the only way of treatment for cancer-related
anemia. This had several limitations: the risk of an allogeneic blood transfusion on
itself, and the temporary effect and benefit for the patient. There also was a delay of
anemia treatment as transfusion was usually not given in case of mild or moderate
anemia, but only in case of more severe anemia (hemoglobin [Hb] ≤8 g/dL).
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The primary regulator of erythropoiesis is
erythropoietin (EPO), a glycoprotein hormone produced
in the kidney, stimulated by tissue hypoxia. The EPO gene
sequence is known since 1985 (Lin et al 1985). This
allowed the development of recombinant human
erythropoietin (rHuEPO), offering an alternative to
transfusion in anemic patients: first in anemia due to
chronic renal disease (Eschbach et al 1987, 1989) and
later also in chemotherapy-induced anemia (CIA)
(Cascinu et al 1994). At the moment different
erythropoietic agents are available: Epoetin alfa (Procrit,
Amgen, Thousand Oaks, USA/Ortho Biotech,
Bridgewater, USA; Epogen, Amgen, Thousand Oaks,
USA; Eprex, Janssen/Cilag, Beerse, Belgium); Epoetin
beta (NeoRecormon, Roche, Basel, Switzerland) and
Darbepoetin alfa (Aranesp, Amgen, Thousand Oaks,
USA).
Recombinant human erythropoietin therapy has well
documented clinical benefits, but frequent dosing is
required and response rate is variable. Darbepoetin alfa
is a new-generation molecule with clear advantages
compared with rHuEPO. This article provides an
overview of the evidence for the use of Darbepoetin alfa
in patients with CIA.
Darbepoetin alfa
Erythropoietin research demonstrated that the carbohydrate
content, more specifically the sialic acid residues, is the
determining factor for the in vivo (not in vitro) biological
activity. Studies on isolated rHuEPO isoforms showed that
molecules with the highest sialic acid content had the longest
plasma half-life and the greatest in vivo bioactivity, but a
lower receptor affinity (Darling et al 2002). Clearance and
not receptor affinity seemed to be the key factor for enhanced
in vivo bioactivity. Five amino-acid changes were designed
in Darbepoetin alfa compared with rHuEPO. This enabled
the addition of 2 new carbohydrate chains at unique sites of
the protein backbone, resulting in a total of 5 N-linked
carbohydrate chains compared with 3 in rHuEPO. In
summary, the new molecule was distinct from epoetin with
regard to physical size, molecular weight, carbohydrate, and
sialic acid content. Darbepoetin alfa works through
interaction with the EPO-receptor to promote proliferation,
survival, and differentiation of hematopoietic cells in a
manner consistent with the activity of endogenous EPO
(Egrie et al 2003).
In a comparative study of rHuEPO and Darbepoetin alfa
in vivo, Egrie et al (2003) demonstrated that Darbepoetin
alfa has a 3-fold longer circulating half-life in rats and dogs,
and that it is more potent than rHuEPO.
Pharmacokinetics and
pharmacodynamics
Pharmacokinetic studies with Darbepoetin alfa have been
completed in a range of patient populations, including
healthy volunteers, patients with end-stage renal failure, and
with CIA. In those studies in which comparisons to rHuEPO
have been done, Darbepoetin alfa was consistently cleared
more slowly, with a longer terminal half-life compared with
rHuEPO (Allon et al 2002). Pharmacokinetic properties of
Darbepoetin alfa administrated subcutaneously were studied
in patients receiving chemotherapy every 3 weeks. Peak
concentration (median) occurred at 62 and 72 hours post-
dose, and mean (SD) terminal half-life ranged from 87.7
(26.0) to 60.9 (22.3) hours (Heatherington et al 2001). These
studies already suggested that dosing less frequently than
the 3-times-weekly doses used for rHuEPO might be
effective.
Pharmacokinetics of Darbepoetin alfa also have been
studied in function of weight, based on a typical oncology
population and with reserve to the weight extremes. Weight
did not seem to have an influence on the efficacy of the
molecule in a phase II randomized, double-blind study
comparing a weight-based versus a fixed dose (Hesketh et
al 2004).
Safety
Darbepoetin alfa is a safe and well-tolerated drug. In all of
the clinical studies reported, adverse events were generally
associated with malignant disease and the toxic effects of
chemotherapy, with no difference between placebo and
Darbepoetin alfa arms. The most frequently reported adverse
events were gastrointestinal (nausea and vomiting) and
constitutional symptoms (fatigue). A broad range of doses
and different administration schedules have been studied,
with no demonstrated dose-effect relationship for adverse
events. Possible thromboembolic complications when using
erythropoietic agents are of particular concern. A recently
published meta-analysis did not suggest an increased risk
(Bohlius, Langensiepen, et al 2005), but an update of that
work, now including 57 trials with 9353 patients, reported
an increased risk of thromboembolic adverse effects (relative
risk [RR] 1.67, 95% confidence index [CI] 1.35–2.06)
(Bohlius, Wilson, et al 2005). Hedenus studied whichTherapeutics and Clinical Risk Management 2006:2(2) 177
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criterion of rise in Hb during Darbepoetin alfa therapy was
the best discriminator between natural Hb variability and
increased risk of thrombotic events (Hedenus, Canon, et al
2005). Three definitions of rapid rise in Hb were considered
(=2 g/dL increase in 28 days; =1.5 g/dL increase in 21 days;
and =1 g/dL increase in 14 days). The 2 g/dL per 28 days
was the best discriminator, while the 1 g/dL rule resulted in
an excessive rate of “false-positive” risk, even in the absence
of erythropoietic therapy. The elucidation of this safety
aspect is crucial for the future of eryhropoietic therapy.
One study evaluated fixed dose versus weight-based dose
of Darbepoetin alfa and observed no safety problems, with
a reservation for the extremes of weight, because of the
limited number of these type of patients in the study (Hesketh
et al 2004).
Pure red cell aplasia (PRCA) in association with
neutralizing antibodies to endogenous EPO has been
observed in patients with chronic kidney disease who had
been treated by subcutaneous injection of one brand of
Epoetin alfa (Eprex) (Casadevall et al 2002; Macdougall
2004). To date, there is no evidence of neutralizing
antibodies to Darbepoetin alfa.
An other ongoing safety issue is the exclusion of any
adverse effect concerning progression-free or overall
survival in patients treated with erythropoietic agents (see
“Effect on disease outcome”).
Clinical efficacy
Treatment of CIA with Darbepoetin alfa
administered once weekly
The clinical efficacy of Darbepoetin alfa once weekly has
been established in several phase II and III randomized trials
(Table 1).
Glaspy et al (2002) administered Darbepoetin alfa to
anemic patients with solid tumors receiving chemotherapy
at doses of 0.5 µg/kg to 8.0 µg/kg once a week (n=216);
Epoetin alfa, in an initial dose of 150 U/kg 3 times weekly,
with possible dose increase to 300 U/kg, 3 times weekly
was the control arm (n=53). There was an evident dose-
response relationship for Hb response (ie, an increase in
Hb concentration from baseline of at least 2 g/dL) up to doses
of 4.5 µg/kg. At this dose, 76% of the patients had a Hb
response (95% CI 59–94). In a later part of this study,
administration of Darbepoetin alfa every 2 weeks proved
to result in similar efficacy. In another phase II randomized
study, Hedenus et al (2002) evaluated the efficacy of 3 doses
of Darbepoetin alfa (1.0 µg/kg, 2.25 µg/kg, and 4.5 µg/kg)
(n=55) versus placebo (n=11) in anemic patients with
lymphoproliferative malignancies receiving chemotherapy.
The proportion of patients achieving Hb response was higher
with any dose of Darbepoetin alfa compared with placebo
(45%, 55%, 62% and 10% for a dose of 1.0 µg/kg, 2.25 µg/
kg, and 4.5 µg/kg and placebo respectively; p<0.01).
Table 1 Clinical trials on treatment of chemotherapy-induced anemia with Darbepoetin alfa administered once weekly
Ref n Study design Study population Main results
(Glaspy et al 2002) 269 Phase II randomized, open label Solid tumors; Evident dose-response relationship for
Darbepoetin alfa: 0.5, 1.0, 1.5, 2.25, receiving chemotherapy; Hb response up to doses of 4.5 µg/kg
4.5, 6.0, and 8.0 µg/kg/week Hb ≤1.0 g/dL
versus
Epoetin alfa: 150I U/kg 3 times/week
(increase to 300 IU/kg)
12-week treatment  
(Hedenus et al 66 Phase II randomized, double-blind Lymphoproliferative Proportion of patients achieving Hb
2002) Darbepoetin alfa: 1.0, 2.25, and malignancies receiving response is higher with any dose of
4.5 µg/kg/week chemotherapy; Darbepoetin alfa compared with placebo
versus Hb ≤11.0 g/dL
Placebo: 12-week treatment
(Vansteenkiste 314 Phase III randomized, double-blind Lung cancer receiving Significant reduction of incidence of
et al 2002) Darbepoetin alfa: 2.25 µg/kg/week platinum-based transfusion and number of units
versus chemotherapy; transfused.
Placebo: 12-week treatment Hb ≤11 g/dL Better hematopoietic response and QoL.
(Hedenus et al  344 Phase III randomized, double-blind Lymphoproliferative Significant reduction of RBC transfusions
2003) Darbepoetin alfa: 2.25 µg/kg/week malignancies receiving and higher Hb response.
versus chemotherapy;
Placebo: 12-week treatment Hb ≤11 g/dL
Abbreviations: Hb, hemoglobin; RBC, red blood cells; QoL,quality of life.Therapeutics and Clinical Risk Management 2006:2(2) 178
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Subsequently, two large, placebo-controlled phase III
trials were conducted that confirmed the efficacy of
Darbepoetin alfa at a dose of 2.25 µg/kg per week.
Vansteenkiste et al (2002) randomly assigned 314 anemic
lung cancer patients receiving platinum-containing
chemotherapy (Hb <11 g/dL), to either Darbepoetin alfa
(2.25 µg/kg per week) or placebo. Primary endpoint was
the proportion of patients who needed red blood cell (RBC)
transfusion. There was a statistically significant reduction
of both the incidence of transfusion (reduction of 25%
compared with placebo, 95% CI 14–36, p<0.001) and the
number of units transfused (difference of 1.25 units, 95%
CI 0.65–1.84, p<0.001). The proportion of patients
achieving a hematopoietic response and those with a
decrease in fatigue also were significantly in favour of
Darbepoetin alfa. Hedenus et al (2003) conducted a similar
study in 344 anemic patients with lymphoproliferative
malignancies receiving chemotherapy. A significant higher
Hb response (60% [95% CI 52–68] achieving a Hb response
in the Darbepoetin alfa cohort) and a statistically significant
reduction of transfusions (31% vs 48%, p<0.001) were
noted.
The effect of Darbepoetin alfa was also studied in
patients with anemia of cancer not treated with
chemotherapy (Smith et al 2003). The first open-label part
of this trial included 102 patients, who received doses of
0.5 µg/kg to 4.5 µg/kg once weekly for 12 weeks.
Hematopoietic response was reached in 70% (95% CI 53–
88) at the 2.25 µg/kg dose, and in 100% at the 4.5 µg/kg
dose, both largely superior compared with placebo (10%,
95% CI 0–24).
Treatment of CIA with Darbepoetin alfa
administered every 3 weeks
Many chemotherapy schedules for solid tumors are
administered in a cycle length of 3 weeks. Therefore,
extension of the dosing interval of erythropoietic therapy
to once every 3 weeks was considered to be of major interest.
Darbepoetin alfa, with its longer serum half-life compared
with rHuEPO, was an ideal candidate to explore this option
(Table 2).
Kotasek et al (2003) conducted a placebo-controlled,
safety and dose-finding study with administration of
Darbepoetin alfa every 3 weeks in anemic patients with solid
tumors (n=249). Doses ranged from 4.5 µg/kg to as high as
15 µg/kg in the active arms. Administration of a high dose
every 3 weeks proved to be safe. There was a dose-response
relationship for Hb and hematopoietic response up to doses
of 12.0 µg/kg, and the optimal dose for further development
was set at 6.75 µg/kg every 3 weeks.
Synchronous administration of chemotherapy and
erythropoietic therapy on an every 3 weeks basis was the
most attractive option for both patients and caregivers.
Because of the negative historical experience with
synchronous use of neutrophil growth factors and
chemo(radio)therapy (Bunn et al 1995), similar concerns
Table 2 Clinical trials on treatment of chemotherapy-induced anemia with Darbepoetin alfa administered once every 3 weeks
Ref n Study design Study population Main results
(Kotasek et al 2003) 249 Phase II randomized, double-blind Solid tumors receiving Evident dose-response relationship
Darbepoetin alfa: 4.5, 6.75, 9.0, 12.0, 1 chemotherapy; for hematopoietic response and
3.5, and 15 µg/kg every 3 weeks Hb ≤11.0 g/dL mean change in Hb up to doses
versus 12.0 µg/kg
Placebo: 12-week treatment Lower percentage of patients
receiving RBC transfusions (any
group) compared with placebo
(Glaspy et al 2005) 81 Phase II randomized, open label Non myeloid Similar mean increase in Hb after
Darbepoetin alfa 6.75 µg/kg every malignancies receiving 6 weeks
3 weeks synchronous (day 1) chemotherapy;
versus Hb ≤11 g/dL
asynchronous (day 15) with
chemotherapy: 16-week treatment
(Canon et al 2006) 705 Phase III randomized, double blind Non-myeloid Noninferiority of every 3 weeks
Darbepoetin alfa 500 µg every 3 weeks malignancies receiving dosing versus every week dosing
versus chemotherapy;
Darbepoetin alfa 2.25 µg/kg every Hb ≤11 g/dL
week: 16-week treatment
Abbreviations: Hb, hemoglobin; RBC, red blood cellsTherapeutics and Clinical Risk Management 2006:2(2) 179
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were raised about administration of erythropoietic agents
on the day when bone marrow precursors were hit by
chemotherapy. This important question was addressed in a
phase II randomized study (Glaspy et al 2005). As many
aspects of pharmacokinetics of endogenous and recombinant
human erythropoietin in that setting were not clear, both
efficacy and pharmacokinetic parameters were recorded.
Patients (n=81) received chemotherapy every three weeks
and were randomized 1:1 to receive Darbepoetin alfa
6.75 µg/kg once every three weeks asynchronously (day 15)
or synchronously (day 1) with chemotherapy. The primary
endpoint (mean increase in Hb after 6 weeks) was similar
in both groups: 1.0 g/dL (95 %: CI 0.6–1.3) asynchronous,
1.0 g/dL (95 % CI: 0.6–1.5) synchronous (p=0.45) (Figure
1). No significant differences were noted concerning the
importance or rate of Hb change, pointing at similar efficacy
of synchronous or asynchronous dosing. The
pharmacokinetic data showed an increase of endogenous
EPO concentrations in both groups starting 6 hours after
chemotherapy and lasting one week. A possible explanation
for this phenomenon is a decreased clearance by the bone
marrow caused by the myelosuppressive effect of
chemotherapy. Synchronous dosing of chemotherapy and
Darbepoetin alfa also resulted in an increase in maximal
concentration and area under the curve–time curve of
Darbepoetin alfa compared with asynchronous dosing. The
argument that bone marrow contributes to clearance of
erythropoietic proteins is also plausible here. The net result
is a higher availability of Darbepoetin alfa on the days when
myelosuppression due to chemotherapy is more prominent,
resulting in similar efficacy as for asynchronous
administration.
The regimen of Darbepoetin alfa every 3 weeks was
confirmed in a large phase III study (n=705), that was
reported recently (Canon et al 2006). It was a randomized
double-blind, double-dummy, active-controlled study
conducted in anemic (Hb <11 g/dl) patients with
chemotherapy for non-myeloid malignancy, comparing
weekly administration of 2.25 µg/kg Darbepoetin alfa versus
a fixed dose of 500 µg every three weeks. The primary
endpoint was the incidence of RBC transfusions from week
5 to the end of treatment. The study had a noninferiority
design: the upper limit of the 95% CI of the difference in
the incidence of RBC transfusions had to be below 12.5%.
This number was based on the average difference in
transfusion rates of 23% in the two phase III studies with
weekly dosing (Vansteenkiste et al 2002; Hedenus et al
2003). Adjusted for stratification factors, the incidence of
transfusions was 19% (95% CI 15–24) for the every three
weeks and 28% (95% CI 23–33) for the every-week group,
a difference well below the limit of noninferiority. The
validity of Darbepoetin alfa administered every three weeks
is further illustrated in Figure 2. The RBC transfusion rates
are consistently low in all actively treated groups of four
phase III trials with this agent, two placebo-controlled ones
(Vansteenkiste et al 2002; Hedenus et al 2003), one with
front-loaded dosing (Kotasek et al 2004), and the every 3
weeks study (Canon et al 2006).
Figure 1 Mean hemoglobin over time by chemotherapy cycle in the phase II randomized study with asynchronous (filled circles) or synchronous administration
(empty circles) of Darbepoetin alfa administered every 3 weeks. Error bars represent 95% confidence limits. Copyright © 2005. Reproduced with permission from
Glaspy J, Henry D, Patel R, et al. 2005. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of
darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer, 41:1140–9.Therapeutics and Clinical Risk Management 2006:2(2) 180
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Clinical trials on treatment of CIA with
Darbepoetin alfa focusing on special
issues
Front-loaded dosing
Another attractive hypothesis to improve the efficacy of
erythropoietic therapy has been the front-loading approach
with the purpose of achieving an optimal and fast response.
This would also permit to identify non-responders early.
Therapy was started with a dose-intense schedule during a
correction phase (the time needed to reach a Hb value of
≥12 g/dL) with the intent to decrease the dose or increase
the dose interval during a maintenance phase (Table 3).
Two phase II trials explored this concept. In a
randomized, active-controlled pilot trial (n=127) by Glaspy
et al (2003), patients were randomly assigned to 1 of 4
treatment groups for a duration of 12 weeks. In the active
control arm, patients received 40 000 U rHuEPO per week,
with escalation to 60 000 U per week for non-responders.
The Darbepoetin alfa arms were at doses of 4.5 µg/kg per
week until Hb concentration was ≥12 g/dL, then 1.5 µg/kg
per week (group 1), 4.5 µg/kg per week for 4 weeks,
followed by 2.25 µg/kg per week for 8 weeks (group 2) or
3.0 µg/kg every 2 weeks (group 3). A marked increase of
the Hb level was observed early in the treatment period
(week 5) for all the front-loaded regimens. Median time to
Hb response was 50 days for 2 of the 3 groups treated with
Darbepoetin alfa. The proportion of patients achieving Hb
response varied from 58% to 65% over the 3 Darbepoetin
alfa groups. The limited number of patients permitted not
to make final conclusions concerning efficacy endpoints but
the data were encouraging. Another open label, phase II
randomized study by Hesketh et al (2004) was promising
as well. In a front-loaded schedule, 243 patients received
Darbepoetin alfa every week during the correction phase
(ie, the phase until a Hb concentration ≥12 g/dL was
achieved without a RBC transfusion in the previous 4 weeks)
followed by an administration every 3 weeks during the
maintenance phase (ie, until week 16). Patients were divided
into a group receiving a fixed-dose (325 µg) and a group
receiving a weight-based dose (4.5 µg/kg) of Darbepoetin
alfa. Almost 80% of the patients achieved Hb correction in
both groups. Median time to correction was 42 days,
identical for both groups.
These promising findings were further explored in a large
double-blind, double-dummy, randomized phase III study
in 727 patients with non-myeloid malignancies and CIA (Hb
≤11 g/dL) (Kotasek et al 2004). The expected advantage of
front-loaded dosing could not be confirmed. Patients were
treated with either Darbepoetin alfa 4.5 µg/kg per week for
4 weeks, followed by maintenance with 4.5 µg/kg every 3
weeks, or Darbepoetin alfa 2.25 µg/kg per week, for an
interval of 16 weeks. The primary aim of the study was to
prove noninferiority to standard weekly dosing by evaluating
the number of transfusions. No difference in number of
transfusions from week 5 to the end of treatment was seen
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Figure 2 Red blood cell transfusion rates in four phase III trials with Darbepoetin alfa. Data from two placebo-controlled studies (Vansteenkiste et al 2002; Hedenus
et al 2003), the front-loading study (Kotasek et al 2004), and the every 3 weeks dosing study (Canon et al 2006).
Vansteenkiste Hedenus Kotasek Canon
    Placebo 2.25    Placebo 2.25       2.25 4.5       2.25 500
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between both groups: 24% (95% CI 19–28) for the 2.25 µg/
kg every-week group versus 25 % (95% CI 20–30) for the
front-loaded group. The hematopoietic response level was
higher when Darbepoetin alfa was administered every week
(87%, 95% CI 83–91) compared with the correction/
maintenance approach (68%, 62–73). In conclusion, front-
loading using this administration schedule of Darbepoetin
alfa was of no additional benefit compared with standard
therapy, taken in account that standard therapy appeared to
be very efficient.
Subcutaneous versus intravenous administration
To make Darbepoetin alfa therapy still more convenient,
especially for patients with central venous access, the
efficacy of intravenous administration has been studied
(Table 3). A total of 120 anemic patients with non-myeloid
malignancies planned to receive 12 additional weeks of
chemotherapy, were randomly assigned (1:1 allocation) to
subcutaneous or intravenous administration (Justice et al
2005). During a correction phase lasting from week 1 to 6,
each group received Darbepoetin alfa 4.5 µg/kg weekly,
followed by a less frequent dose of 4.5 µg/kg every 3 weeks
during a maintenance phase (until week 15). Primary
endpoint was the change in Hb from baseline. The mean
change in Hb (intention-to-treat) was 1.0 g/dL (95 % CI 0.6–
1.4) in the intravenous group and 1.4 g/dL (95% CI 1.0–
1.9) in the subcutaneous group. This difference between
both groups was not statistically significant. Results for other
endpoints such as hematopoietic response and number of
RBC transfusions were similar as well. Pharmacokinetic
analyses showed no accumulation of Darbepoetin alfa, even
not during the correction phase. Efficacy is similar
considering both ways of administration.
Future issues with Darbepoetin
alfa therapy
Iron supplementation
Another open question in the treatment of CIA is the role of
iron supplementation. When plasma iron values and iron
reserve values are low (saturation <20%), iron substitution
seems attractive. Whether oral or intravenous iron has to be
preferred remains unsolved. Intravenous iron improves Hb
response and decreases dosage requirements in patients with
anemia of kidney disease, but its effect is less documented
in cancer patients.
In a prospective, multicenter, open-label, randomized
trial, Auerbach et al (2004) studied 157 patients with
chemotherapy-related anemia (Hb <10.5 g/dL) receiving
rHuEPO 40 000 U once weekly with either no iron, oral
iron 325 mg twice daily, or iron dextran intravenously.
Mean Hb increase was significantly better with
intravenous iron than with no or oral iron. The
hematopoietic response was 68% with intravenous iron,
compared with 36% with oral iron, and 25% without iron.
The interpretation of these findings is difficult, as the
very low hematopoietic response in the cohorts with oral
or no iron is not in line with any other study with
erythropoietic agents. This suggests inclusion of a special
selection of patients, probably those with severe iron
deficiency, as one of the inclusion criteria of the trial
was an iron saturation below 19%.
A study in a less selected group of patients receiving
chemotherapy is ongoing. The hematopoietic response after
16 weeks of treatment with 500 µg of Darbepoetin alfa every
three weeks with either intravenous iron versus oral or no
iron supplementation according to local practice will be
compared. This study will hopefully lead to a better
understanding of the iron issue.
Effect on disease outcome
The positive effect of the treatment of anemia on health-
related QoL is well established. It is also clear that anemia
is an independent negative prognostic factor, with
growing evidence for other consequences of anemia in
patients with cancer such as increased resistance to
therapy, increased tumor invasiveness, and metastatic
potential, resulting in reduced survival (Caro et al 2001).
The question of whether correction of anemia during
oncological treatment can favourably influence outcome,
however, remains unresolved at the moment. Encouraging
findings in this respect were present in recent randomized
trials. In our phase III study, the hypothesis of a
potentially better survival in patients with small cell lung
cancer treated with Darbepoetin alfa versus those
receiving placebo was generated (Vansteenkiste et al
2002). A possible relationship between increased Hb and
better survival was also reported in a phase III study on
375 anemic (Hb <10.5 g/dL) patients with solid or
nonmyeloid hematological malignancies treated with
non-platinum chemotherapy (Littlewood et al 2001). A
similar, but also nonsignificant,
 trend towards improved
survival with rHuEPO was observed in another placebo-
controlled study (Witzig et al 2004).Therapeutics and Clinical Risk Management 2006:2(2) 182
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On the other hand, caution was raised recently, following
two studies with rHuEPO in breast cancer and head and
neck cancer reporting negative survival results. The first
one was a placebo-controlled study in patients with
metastatic breast cancer that was prematurely stopped
because of a statistically significant higher mortality in
the Epoetin alfa group (Leyland-Jones et al 2005). There
was an excess mortality during the first 4 months of
treatment, due to an increased incidence of both tumor
progression as well as thrombotic vascular events. After
the initial excess in deaths in the active arm, overall time
to progression was similar in both arms. No definitive
conclusions can be made regarding tumor progression
rates, however, because of the lack of data on many
potentially important prognostic factors that might have
affected study outcome. External review by an
independent group of researchers even suggested worse
prognostic features for the Epoetin alfa group in terms
of age, performance status, disease extent, degree of
baseline anemia, and thromboembolic risk.
The second study was a randomized double-blind
placebo-controlled study including 351 anemic patients with
head and neck cancer (Henke et al 2003). Locoregional
progression-free survival (the primary endpoint) was worse
with Epoetin beta than with placebo (adjusted RR 1.62, 95%
CI 1.22–2.14, p=0.0008). The study has been criticized for
several reasons. First, there were potential imbalances in
study populations across arms, as there were more smokers
(with possibly increased co-morbidity) and relapsed patients
in the Epoetin beta arm, and as no data on performance
status were available. Second, protocol violations were
present in 36% of the patients, and the difference in outcome
Table 3 Clinical trials on treatment of chemotherapy-induced anemia with Darbepoetin alfa focusing on special issues
Ref n Study design Study Main results
population
Front-loaded dosing
(Glaspy et al 2003) 127 Phase II randomized, double-blind Solid tumors Safe and effective improvement of Hb
Darbepoetin alfa : 4.5 µg/kg/week receiving concentration
until Hgb=12 g/dL,  then chemotherapy;
1.5 µg/kg/week (Group 1) Hb ≤11 g/dL
4.5 µg/kg/week for 4 weeks, then
2.25 µg/kg/week (Group 2)
4.5 µg/kg/week for 4 weeks, then
3.0 µg/kg every 2 weeks (Group 3)
versus
rHuEPO 40 000 U/week (increase
to 60 000 U/week): 12-week treatment
(Hesketh et al 2004) 243 Phase II randomized, double-blind Non-myeloid High hematopoietic response in both the
Darbepoetin alfa fixed dose malignancies, fixed-dose group (86%) and weight-based
(325 µg/week) receiving dose group (84%). Similar median time to
versus chemotherapy; hematopoietic response.
Darbepoetin alfa weight-based dose Hb ≤11.0 g/dL Hb concentrations maintained at target
(4.5 µg/kg/week), until Hb =12.0 g/dL, levels for up to 16 weeks in both groups
followed by administration every
3 weeks: 16-week treatment
(Kotasek et al 2004) 727 Phase III randomized, double-blind, Non-myeloid Noninferiority of front-loading compared with
active-controlled malignancies, standard weekly dosing
Darbepoetin alfa 2.25 µg/kg/week receiving Better hematopoietic response in standard
versus chemotherapy; weekly dosing
Darbepoetin alfa 4.5 µg/kg/week for Hb ≤11.0 g/dL
4 weeks, then 4.5 µg/kg every 3 weeks
Subcutaneous versus intravenous administration
(Justice et al 2005) 118 Phase II randomized, open label Non-myeloid Equal efficacy of Darbepoetin alfa administered
Darbepoetin alfa 4.5 µg/kg for 6 weeks, malignancies, IV or SC
followed by 4.5 µg/kg every 3 weeks for receiving
12 weeks subcutaneous chemotherapy;
versus Hb ≤11.0 g/dL
Same schedule intravenous
18-week treatment
Abbreviations: Hb, hemoglobin; IV, intravenous; SC, subcutaneous.Therapeutics and Clinical Risk Management 2006:2(2) 183
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was no longer significant when the analysis was restricted
to the as-per-protocol treated patients. Third, the Hb ranges
were far above those usually reported in other studies on
erythropoietic agents: treatment changes were to be made
only if Hb values exceeded 14 g/dL in women or 15 g/dL in
men, or when Hb increased more than 2 g/dL in one week.
The mean Hb concentration at 4 weeks in this cancer
population was 14.8 g/dL.
The results of these two studies (Henke et al 2003;
Leyland-Jones et al 2005) are in contrast with previous trials
(Littlewood et al 2001; Vansteenkiste et al 2002; Witzig et
al 2004), and with the conclusion of a published meta-
analysis based on 27 trials involving 3287 adult patients.
Overall, there was a slightly more favourable meta-analytic
survival outcome in the erythropoietin-treated patients
(hazard ratio [HR] 0.81, 95% CI 0.67–0.99). This meta-
analysis has been updated recently. The study now concerns
57 trials with 9353 patients, including the two trials with
negative impact on survival. Positive results on reduced risk
of transfusion and presence of hematological response were
maintained. The incidence of thromboembolic
complications was increased (as mentioned in “Safety”).
As for survival, the initially suggested possible benefits
did no longer hold true (HR 1.08; 95% CI 0.99–1.18; 42
trials, n=8167). The authors tried to explain the change
in conclusion by pointing at possible factors such as
thromboembolic complications, tumor progression issues,
but also the methodological limitations of some studies.
As a whole, the evidence confirms the value of
erythropoietic therapy in reducing transfusions and
improving QoL in established indications such as CIA,
but further elucidation of the effect of erythropoietic
therapy when used to obtain high-normal Hb values in
an attempt to improve outcome is clearly needed.
It should also be noted that no similar problems with
Darbepoetin alfa have occurred. In a recent combined
analysis of four studies, including the two randomized,
double-blind, placebo-controlled phase III studies of weekly
dosing of Darbepoetin alfa, the prospectively defined short-
and long-term progression-free and overall survival
endpoints were not different across arms (HR 0.92; 95% CI
0.78–1.07; 0.95; 95% CI 0.78–1.16, respectively) (Figure
3) (Hedenus, Vansteenkiste, et al 2005). Different
erythropoietic proteins such as Epoetin alfa or beta or
Darbepoetin alfa have unique pharmacokinetics, and this
may be accompanied by distinct effects on survival.
 The
dose and schedule of erythropoietic therapy may also be
important, as well as the chosen target Hb to act on survival.
Several ongoing placebo-controlled trials with Darbepoetin
alfa in different tumor types are studying these important
questions.
Conclusion
Anemia is frequent in cancer patients with chemotherapy,
and has an important negative effect on health-related QoL.
Darbepoetin alfa, the first of a novel generation of
erythropoietic agents, has been confirmed to be effective
when administered once weekly at a dose of 2.25 µg/kg in
two large phase III placebo-controlled trials in patients with
solid tumors and hematological malignancies. Furthermore,
it was a safe and well tolerated drug. More recently, different
other issues have been studied. Front-loaded dosing was
explored to accelerate the Hb response and effect on QoL.
Phase II data were promising, but no benefit compared with
standard dosing could be shown in a large phase III study.
In an attempt to further increase convenience for patients
and caregivers, extending the dose interval to every three
Figure 3 Combined analysis of survival from four Darbepoetin alfa studies in chemotherapy-induced anemia.Therapeutics and Clinical Risk Management 2006:2(2) 184
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weeks and thereby adapting the dose frequency to the most
common chemotherapy schedules was studied. In a large
phase III trial, administration of 500 µg every 3 weeks was
not inferior to the weekly dosing, both in reduction of RBC
transfusion, Hb parameters, and QoL. This clinically
attractive schedule has been approved by the European
Agency for the Evaluation of Medicinal Products (EMEA)
and approval by the Food and Drug Administration (FDA)
is pending. When using Darbepoetin alfa every 3 weeks,
efficacy is similar when Darbepoetin alfa is administered
synchronous or asynchronous with chemotherapy. For daily
practice it is obvious that administration on the same day
just prior to the chemotherapy is preferred.
Issues for future study are the optimal iron
supplementation strategy and the effect of erythropoietic
therapy on outcome. The last issue is a hot topic, especially
after recent negative results of two outcome studies with
rHuEPO that targeted normal to high Hb levels. No final
conclusions can be made, as these two studies had
methodological flaws and are in conflict with other studies.
The influence of erythropoietic therapy on outcome remains
a very attractive field of investigation, and the results of
ongoing survival studies are eagerly awaited.
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